
    
      This is a Phase 1 open-label dose-escalating trial designed to determine the dose-limiting
      toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics of a single dose of MLN2704
      in subjects with metastatic androgen-independent prostate cancer.
    
  